Immunotherapy with ciamexon in the non obese diabetic (NOD) mouse.
Ciamexon (CMX), a new immunomodulatory compound acting mainly on B-lymphocytes was given orally to 42 NOD mice divided into three sex and litter matched groups (A: 0.3 mg/mouse/day CMX, B: 1.5 mg/mouse/day CMX, C: control) from 7 weeks of age. Animals were followed up for evaluation of diabetes incidence up to 32 weeks of age. There was a tendency for a delayed onset of hyperglycemia in mice of group B up to 26 weeks of age; however no significant difference in the cumulative incidence of diabetes at 32 weeks of age was observed (A: 57.5%, B: 38.5%, C: 38.5%). No differences were found in the number of infiltrated islets in animals culled at 10 weeks of age treated with CMX from 4 weeks of age. We conclude that CMX does not modify the course of insulitis and diabetes incidence in NOD mice although though the appearance of glycosuria was delayed by this treatment.
Krug
J
J
Department of Diabetes and Metabolism, St. Bartholomew's Hospital, London, United Kingdom.
Lampeter
E F
EF
Williams
A J
AJ
Procaccini
E
E
Cartledge
C
C
Signore
A
A
Beales
P E
PE
Pozzilli
P
P
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D001388:Aziridines / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000628:therapy* / Q000652:urine; D005260:Female; D006029:Glycosuria / Q000378:metabolism; D007074:Immunoglobulin G / Q000096:biosynthesis; D008297:Male; D051379:Mice; D016688:Mice, Inbred NOD; D012756:Sheep / Q000276:immunology
D000276:Adjuvants, Immunologic; D001388:Aziridines; D007074:Immunoglobulin G; C035520:ciamexon